Cancer Diagnosis
Conditions
Keywords
Cancer Diagnosis
Brief summary
The purpose of this research study is to evaluate the possible benefits of an investigational, but commercially available Galleri multi-cancer early detection (MCED) blood test which is designed to detect many types of cancer early in veterans who have served in the military in active duty. The name of the screening blood test being studied is: -GRAIL Galleri MCED test
Detailed description
This research study aims to assess the performance of the Galleri multi-cancer early detection (MCED) screening test in a military population and to compare the number and types of cancers diagnosed using MCED testing versus standard of care. This research study will give doctors and participants results of Galleri® blood tests which is designed to detect many types of cancer. The research study procedures including screening for eligibility, blood draws, questionnaires, and clinic visits. Participation in this research study is expected to last for up to 1 year. It is expected that about 1,500 people will take part in this research study. The Department of Defense (DoD) is funding this study.
Interventions
OTHERGRAIL Galleri
A multi-cancer early detection (MCED) blood test.
Sponsors
Dana-Farber Cancer Institute
United States Department of Defense
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
45 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Active-duty or National Guard/Reserves military service for four or more years * Age ≥ 45 * Received care at a VA facility within past 5 years * Able to sign informed consent * Willingness to travel to Dana-Farber Cancer Institute in Boston, MA, for diagnostic testing if screening test indicates possible malignancy
Exclusion criteria
* Individuals diagnosed with invasive malignancy within 3 years of enrollment (non- melanoma skin cancer is acceptable) * Individuals with evidence of symptomatic or active cancer requiring therapeutic intervention at the time of participation (hormone therapy for breast/prostate cancer is acceptable) * Individuals in the process of being evaluated for a clinical suspicion of cancer
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Positive predictive value at 12 Months | At 12 months | Positive predictive value is defined as the proportion of participants with cancer diagnosis out of all participants with "signal detected" on GRAIL Galleri MCED test results. |
| Negative predictive value at 12 Months | At 12 months | Negative predictive value is defined as the proportion of participants with no cancer diagnosis out of all participants with "signal not detected" on GRAIL Galleri MCED test results. |
| Specificity Rate at 12 Months | At 12 months | Specificity is defined as the proportion of participants with "signal not detected" results out of all participants with no cancer diagnosis on GRAIL Galleri MCED test results. |
| Yield Rate at 12 Months | At 12 months | Yield rate is defined as the proportion of participants with "signal detected" out of all participants tested on GRAIL Galleri MCED test. |
| Number of Participants Needed to Screen at 12 months | At 12 months | Number Needed to Screen (NNS) is defined as the number of participants screened to detect a diagnosis of invasive cancer on the GRAIL Galleri MCED test. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cancer Detection Rate Comparison | Up to 12 months | Descriptive statistics will be used to summarize the number and types of cancers diagnosed by GRAIL Galleri MCED testing compared to Standard of Care (SOC) in matched population from the VA (separate IRB protocol). |
| Stage of Invasive Cancer Diagnosis Comparison | Up to 12 months | Descriptive statistics will be used to summarize the stages of invasive cancer that are diagnosed by GRAIL Galleri MCED testing assessed by medical record review compared to Standard of Care (SOC) in matched population from the VA (separate IRB protocol). |
| Change in PROMIS Anxiety Short Form Score | Baseline to 12 months | Changes in anxiety following the GRAIL Galleri MCED test result and assessed by the Patient-Reported Outcome Measurement Information System (PROMIS) Emotional Distress Anxiety - Short Form 6a, which is a 6 item survey that is rated on a 5-point Likert scale with answers ranging from "Never" to "Always". The range of scoring is from 6 to 30 with higher scores indicating greater severity of anxiety. |
| Change in PROMIS Global Health Score | Baseline to 12 months | Changes in health-related quality of life following the GRAIL Galleri MCED test result and assessed by PROMIS Scale v1.2 - Global Health, a 10 item survey that is rated on a 5-point Likert scale with answers ranging from "Excellent/Completely/Never/None" to "Poor/Not at all/Always/Very Severe" and includes a pain average question rated on a scale of 0 "No Pain" to 10 "Worst Pain Imaginable." The range of scoring is from 9 to 45 with higher scores indicating higher quality of life. |
Countries
United States
Contacts
CONTACTElizabeth ODonnell, MD
PRINCIPAL_INVESTIGATORElizabeth ODonnell, MD
Dana-Farber Cancer Institute
Outcome results
None listed